Telix Pharmaceuticals Limited announced that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB™, at the Royal Adelaide Hospital.
The clinical study which is being conducted by the Central Adelaide Local Health Network is co-funded by Telix and strategic partner, AusHealth®.
Moreover, the trial’s principle investigator Professor Michael Brown said “The dosing of these first patients is the culmination of more than a decade of fundamental research around a novel oncology target, and enables the evaluation of the potential of APOMAB as a targeting agent for imaging and therapy.”